Jankowski J, Floege J, Fliser D, Böhm M, Marx N (2021) Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation 143:1157–1172

Article  PubMed  PubMed Central  CAS  Google Scholar 

Schuett K, Marx N, Lehrke M (2023) The cardio-kidney patient: epidemiology, clinical characteristics and therapy. Circ Res 132:902–914

Article  PubMed  PubMed Central  CAS  Google Scholar 

Vedanthan R, Seligman B, Fuster V (2014) Global perspective on acute coronary syndrome: a burden on the young and poor. Circ Res 114:1959–1975

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ralapanawa U, Sivakanesan R (2021) Epidemiology and the magnitude of coronary artery disease and acute coronary syndrome: a narrative review. J Epidemiol Glob Health 11:169–177

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ferreira-González I (2014) The epidemiology of coronary heart disease. Rev Esp Cardiol (Engl Ed) 67:139–144

Article  PubMed  Google Scholar 

Bagshaw SM, Cruz DN, Aspromonte N et al (2010) Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrol Dial Transplant 25:1406–1416

Article  PubMed  Google Scholar 

Kottgen A, Russell SD, Loehr LR et al (2007) Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 18:1307–1315

Article  PubMed  CAS  Google Scholar 

McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599–3726

Article  PubMed  CAS  Google Scholar 

Yancy CW, Jessup M, Bozkurt B et al (2017) 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 70:776–803

Article  PubMed  Google Scholar 

Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:2129–2200

Article  PubMed  Google Scholar 

McDonagh TA, Metra M, Adamo M, et al. (2021) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4–131.

Anker SD, Butler J, Filippatos G et al (2021) Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-reduced trial. Circulation 143:337–349

Article  PubMed  CAS  Google Scholar 

Solomon SD, McMurray JJV, Claggett B et al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387:1089–1098

Article  PubMed  Google Scholar 

Löfman I, Szummer K, Dahlström U, Jernberg T, Lund LH (2017) Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction. Eur J Heart Fail 19:1606–1614

Article  PubMed  Google Scholar 

Saran R, Robinson B, Abbott KC et al (2019) US renal data system 2018 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 73:A7-a8

Article  PubMed  PubMed Central  Google Scholar 

McAlister FA, Ezekowitz J, Tarantini L et al (2012) Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new Chronic Kidney Disease-Epidemiology Collaboration Group formula. Circ Heart Fail 5:309–314

Article  PubMed  Google Scholar 

Mark PB, Mangion K, Rankin AJ et al (2022) Left ventricular dysfunction with preserved ejection fraction: the most common left ventricular disorder in chronic kidney disease patients. Clin Kidney J 15:2186–2199

Article  PubMed  PubMed Central  Google Scholar 

De Lima JJG, Macedo TA, Gowdak LHW, David-Neto E, Bortolotto LA (2022) Diastolic and systolic left ventricular dysfunction and mortality in chronic kidney disease patients on haemodialysis. Nephrology (Carlton) 27:66–73

Article  PubMed  Google Scholar 

Kang E, Lee SW, Ryu H et al (2022) Left ventricular diastolic dysfunction and progression of chronic kidney disease: analysis of KNOW-CKD data. J Am Heart Assoc 11:e025554

Article  PubMed  PubMed Central  CAS  Google Scholar 

Borrelli S, De Nicola L, Garofalo C et al (2022) Prevalence and renal prognosis of left ventricular diastolic dysfunction in non-dialysis chronic kidney disease patients with preserved systolic function. J Hypertens 40:723–731

Article  PubMed  CAS  Google Scholar 

Suh SH, Oh TR, Choi HS et al (2022) Association of left ventricular diastolic dysfunction with cardiovascular outcomes in patients with pre-dialysis chronic kidney disease: findings from KNOW-CKD study. Front Cardiovasc Med 9:844312

Article  PubMed  PubMed Central  Google Scholar 

Singh A, Ward RP (2016) Appropriate use criteria for echocardiography: evolving applications in the era of value-based healthcare. Curr Cardiol Rep 18:93

Article  PubMed  PubMed Central  Google Scholar 

Kearns AE, Khosla S, Kostenuik PJ (2008) Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 29:155–192

Article  PubMed  CAS  Google Scholar 

Schneeweis LA, Willard D, Milla ME (2005) Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-kappaB ligand. J Biol Chem 280:41155–41164

Article  PubMed  CAS  Google Scholar 

Simonet WS, Lacey DL, Dunstan CR et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319

Article  PubMed  CAS  Google Scholar 

Yamaguchi K, Kinosaki M, Goto M et al (1998) Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem 273:5117–5123

Article  PubMed  CAS  Google Scholar 

Blázquez-Medela AM, García-Ortiz L, Gómez-Marcos MA et al (2012) Osteoprotegerin is associated with cardiovascular risk in hypertension and/or diabetes. Eur J Clin Invest 42:548–556

Article  PubMed  Google Scholar 

Yilmaz MI, Siriopol D, Saglam M et al (2016) Osteoprotegerin in chronic kidney disease: associations with vascular damage and cardiovascular events. Calcif Tissue Int 99:121–130

Article  PubMed  CAS  Google Scholar 

Bjerre M, Hilden J, Winkel P et al (2020) Serum osteoprotegerin as a long-term predictor for patients with stable coronary artery disease and its association with diabetes and statin treatment: a CLARICOR trial 10-year follow-up substudy. Atherosclerosis 301:8–14

Article  PubMed  CAS  Google Scholar 

Tousoulis D, Siasos G, Maniatis K et al (2013) Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease. Int J Cardiol 167:1924–1928

Article  PubMed  Google Scholar 

Oh KH, Park SK, Park HC et al (2014) KNOW-CKD (KoreaN cohort study for Outcome in patients With Chronic Kidney Disease): design and methods. BMC Nephrol 15:80

Article  PubMed  PubMed Central  Google Scholar 

Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612

Article  PubMed